BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 7524753)

  • 41. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Successful engraftment of T-cell undepleted haploidentical transplants by donor primed with G-CSF and additional use of ATG and MMF for recipients].
    Chen HR; Ji SQ; Yan HM; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Dec; 10(6):548-52. PubMed ID: 12513719
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
    Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
    Chen HR; Ji SQ; Wang HX; Yan HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen.
    Lacerda JF; Martins C; Carmo JA; Lourenço F; Juncal C; Rodrigues A; Vilalobos I; Moura MC; Ligeiro D; Martinho A; Lacerda JM
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):633-42. PubMed ID: 14569559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion.
    Chen HR; Ji SQ; Wang HX; Yan HM; Zhu L; Liu J; Xue M; Xun CQ
    Exp Hematol; 2003 Nov; 31(11):1019-25. PubMed ID: 14585364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis.
    Xu LP; Liu KY; Liu DH; Chen H; Han W; Chen YH; Wang Y; Huang XJ
    Bone Marrow Transplant; 2010 Jun; 45(6):985-92. PubMed ID: 19898505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
    Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
    Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up after allogeneic granulocyte colony-stimulating factor--primed bone marrow transplantation.
    Isola L; Scigliano E; Fruchtman S
    Biol Blood Marrow Transplant; 2000; 6(4A):428-33. PubMed ID: 10975511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia.
    Sodani P; Isgrò A; Gaziev J; Polchi P; Paciaroni K; Marziali M; Simone MD; Roveda A; Montuoro A; Alfieri C; De Angelis G; Gallucci C; Erer B; Isacchi G; Zinno F; Adorno G; Lanti A; Faulkner L; Testi M; Andreani M; Lucarelli G
    Blood; 2010 Feb; 115(6):1296-302. PubMed ID: 19897573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
    Lee KH; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Hwang HJ; Jung AR; Kim SH; Yun SC; Shin HJ
    Blood; 2011 Sep; 118(9):2609-17. PubMed ID: 21715313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.
    Morton J; Hutchins C; Durrant S
    Blood; 2001 Dec; 98(12):3186-91. PubMed ID: 11719353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
    Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical investigation on treatment of children leukemia with non-T-cell depleted haploidentical bone marrow transplantation].
    Yan HM; Ji SQ; Chen HR; Duan LN; Zhu L; Liu J; Xue M; Ding L; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):101-5. PubMed ID: 18315910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors influencing engraftment in HLA-haploidentical/mismatch related transplantation with combined granulocyte-colony stimulating factor-mobilized peripheral blood and bone marrow for patients with leukemia.
    Zhang C; Zhang X; Chen XH; Gao L; Gao L; Kong PY; Peng XG; Sun AH; Wang QY
    Transfus Apher Sci; 2011 Jun; 44(3):249-55. PubMed ID: 21550308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA.
    Mackinnon S; Barnett L; Bourhis JH; Black P; Heller G; O'Reilly RJ
    Blood; 1992 Dec; 80(12):3235-41. PubMed ID: 1467526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.